drugset

drugset / Trial / NCT04594850

Clinical Trial to Evaluate Efficacy and Safety of of Autologous Mesenchymal Stem Cells (MSC) Injected Intracavernously

NCT04594850 ↗

Phase 2 Completed 54 enrolled Pharmicell Co., Ltd.

RandomizedParallel-groupSingle-blindTreatment

Summary

This phase II clinical trial is designed to evaluate the efficacy and safety of autologous Mesenchymal Stem Cells (MSC) injected intracavernously.

Timeline

Start: 2020-10-19
Primary completion: 2026-01-07
Completion: 2026-01-07

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Mesenchymal stem cell	Cell therapy	—	Other

Indications